Why Antibiotic Trials Are Hard
Quick Facts
Why Is Antimicrobial Resistance Such a Serious Public Health Threat?
The US Centers for Disease Control and Prevention estimated in its 2019 Antibiotic Resistance Threats report that more than 2.8 million antibiotic-resistant infections occur in the United States each year, resulting in more than 35,000 deaths. Globally, the Global Research on Antimicrobial Resistance (GRAM) analysis published in The Lancet in 2024 estimated that bacterial antimicrobial resistance was directly responsible for about 1.14 million deaths in 2021 and associated with roughly 4.71 million, with projections of substantial increases by 2050 if trends continue.
Resistance develops when bacteria survive antibiotic exposure and pass on the traits that allowed them to do so. Overuse and misuse of antibiotics in human medicine and agriculture accelerate this process. The consequences reach beyond infectious disease, since surgery, cancer chemotherapy, organ transplantation and neonatal care all rely on effective antibiotics to prevent and treat infection.
What Makes Antibiotic Clinical Trials So Difficult to Design?
Many antibiotic trials use a noninferiority design, asking whether a new drug is not unacceptably worse than an established one. This requires careful choices about the margin of acceptable difference, the clinical endpoint, and the timing of outcome assessment. Because many resistant infections are caused by organisms that standard drugs cannot treat, ethical trials must also provide an effective comparator, which can be difficult when options are limited. Specialists in anti-infective trial methodology have long emphasized that poorly chosen endpoints can obscure whether a drug truly helps patients.
Enrollment is another obstacle. Patients with serious resistant infections are often elderly, have multiple conditions and need treatment within hours, leaving little time for consent and screening. Newer approaches under discussion include rapid diagnostic tests to identify resistant pathogens early, platform trials that test several treatments under one protocol, and endpoints that reflect how patients feel and function rather than only laboratory measures. Public research funders such as the National Institute of Allergy and Infectious Diseases support much of this work, so scientific priorities at such institutes can shape the pace of progress.
What Can Patients and Families Do to Help Slow Antibiotic Resistance?
Antibiotics do not work against viruses such as those that cause colds, influenza and COVID-19, and taking them unnecessarily contributes to resistance. Patients should avoid pressing clinicians for antibiotics when they are not indicated and should never share or save leftover prescriptions. The CDC and WHO both promote antibiotic stewardship programs in hospitals and clinics that aim to ensure the right drug, dose and duration for each patient.
Prevention is equally important. Vaccines against pneumococcus, influenza and other pathogens reduce infections and thus the need for antibiotics. Hand washing, safe food handling and appropriate wound care lower infection risk. Individuals with a persistent or worsening infection should seek medical evaluation, since culture testing can guide targeted therapy.
Frequently Asked Questions
Antibiotics are typically used for short courses and held in reserve to limit resistance, which makes them less commercially attractive than chronic-disease drugs. Combined with the scientific difficulty of trials, this has slowed development, and many experts call for new incentive models.
No. Colds and influenza are caused by viruses, and antibiotics only act against bacteria. Using them for viral illness offers no benefit and promotes resistance.
It is a study designed to show that a new treatment is not meaningfully worse than an existing one, often used when giving a placebo would be unethical because effective therapy exists.
References
- Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019.
- GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990-2021. The Lancet. 2024.
- National Institutes of Health. Dr. John H. Powers III to serve as director of NIH's National Institute of Allergy and Infectious Diseases. NIH News. November 2026.